Ignite Creation Date:
2024-05-05 @ 10:05 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002093
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With AdriamycinBleomycinVincristine ABV in the Treatment of HIV-Associated Kaposis Sarcoma
Sponsor:
Nexstar Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With AdriamycinBleomycinVincristine ABV in the Treatment of HIV-Associated Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
1996-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the toxicity profiles severity and time to onset from initiation of therapy between daunorubicin liposomal and combination chemotherapy with doxorubicinbleomycinvincristine ABV with both regimens administered in combination with antiretroviral therapy To compare the duration of responses response rates and times to response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 103-09 | None | None | None |